
Please try another search
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company’s lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company has commercial development and clinical supply agreement with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Name | Age | Since | Title |
---|---|---|---|
Stefani C. Mancas | 48 | 2018 | Independent Director |
Thomas Cooney | 61 | 2018 | Member of Advisory Board |
Irina Gram-Contulescu | 37 | 2022 | Independent Director |
Anastasia Nichita | - | 2025 | Member of Product Advisory Board |
Radu Bujoreanu | 54 | 2019 | Independent Director |
Srinvas Nalamachu | - | 2018 | Member of Advisory Board |
Mark Hamilton | 39 | 2018 | Independent Director |
Sergei Glinka | 58 | 2024 | Independent Director |
Serguei Melnik | 51 | 2016 | Founder, Acting CEO, President, Company Secretary & Executive Chairman of the Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review